

28 September 2007

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Use of tumour necrosis factor alpha (TNF α) inhibitors (adalimumab, certolizumab and infliximab [review]) for Crohn's disease

Dear consultees and commentators,

Following advice from UCB on the revised timings of the marketing authorisation from EMEA for certolizumab pegol, the process timelines for the Crohn's appraisal have been extended.

The new timelines for this appraisal are as follows:

1 st Committee discussion:	26 March 2008
2 nd Committee discussion:	21 May 2008

This change is with immediate effect and the website will be updated with this information shortly.

Yours sincerely

Eloise Saile
Technology Appraisals Project Manager
Centre for Health Technology Evaluation